BridgeMD
New treatment option for Cachexia
Official title Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms
ClinicalTrials.gov ID: NCT05307367
What this study is testing
- What it's testing
- Muscle mass loss is a common adverse effect of cancer. Muscle mass loss occurs with or without reduction in body weight.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 100. Healthy volunteers may be eligible.
You may be able to join if
- , WP1+WP2X+WP2:
- Men and women at or above the age of 18
- Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb/IV stage not eligible to concurrent chemo/radiation therapy...
- Referred for 1st line palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), this goes for WP1 + WP2
- Referred for palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), for recurrent cancer, this goes only for WP2X.
You likely can't join if
- , WP1+WP2X+WP2:
- Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)
- Local palliative radiotherapy as primary treatment
- ECOG Performance status \> 2
- Physical disabilities excluding physical testing
- Inability to understand Danish
See the full eligibility criteria
- , WP1+WP2X+WP2:
- Men and women at or above the age of 18
- Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb/IV stage not eligible to concurrent chemo/radiation therapy as primary treatment
- Referred for 1st line palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), this goes for WP1 + WP2
- Referred for palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), for recurrent cancer, this goes only for WP2X.
- Having a staging/baseline CT within 4 weeks of initiation of treatment (PET/CT are also allowed), or a baseline scan planned within the first week of treatment.
- ECOG Performance Status 0-2
- Having signed the informed consent form
- , WP1+WP2X+WP2:
- Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)
- Local palliative radiotherapy as primary treatment
- ECOG Performance status \> 2
- Physical disabilities excluding physical testing
- Inability to understand Danish
- Inability to understand scoring systems/patient-reported outcome measures Inclusion Criteria, WP3:
- Men and women above the age of 18
- Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb/IV stage
- ECOG Performance Status 0-2
- Having signed the informed consent form. Exclusion Criteria, WP3:
- Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)
- ECOG Performance Status \> 2
- Physical disabilities excluding physical testing
- Inability to understand Danish
- Inability to understand scoring systems/patient-reported outcome measures
The study team makes the final eligibility decision.
Where it's taking place
- Copenhagen, DK, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 100 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Copenhagen, DK, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.